Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma

Giorgio Perilongo, Rudolf Maibach, Elisabeth Shafford, Laurence Brugieres, Penelope Brock, Bruce Morland, Beatriz de Camargo, Jozsef Zsiros, Derek Roebuck, Arthur Zimmermann, Daniel Aronson, Margaret Childs, Eva Widing, Veronique Laithier, Jack Plaschkes, Jon Pritchard, Marcello Scopinaro, Gordon MacKinlay, Piotr Czauderna

Research output: Contribution to journalArticlepeer-review

175 Citations (Scopus)


Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter).
Original languageEnglish
Pages (from-to)1662-70
Number of pages9
JournalThe New England Journal of Medicine
Issue number17
Publication statusPublished - 22 Oct 2009

Bibliographical note

2009 Massachusetts Medical Society


  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Biopsy
  • Chemotherapy, Adjuvant
  • Child
  • Child, Preschool
  • Cisplatin
  • Disease Progression
  • Doxorubicin
  • Female
  • Hepatoblastoma
  • Humans
  • Infant
  • Liver Neoplasms
  • Male
  • Neoplasm Recurrence, Local
  • Survival Analysis


Dive into the research topics of 'Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma'. Together they form a unique fingerprint.

Cite this